trending Market Intelligence /marketintelligence/en/news-insights/trending/MXd31NClDPCxCo_d4dhhYA2 content esgSubNav
In This List

Akari Therapeutics prices $17.4M offering

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Akari Therapeutics prices $17.4M offering

Akari Therapeutics PLC priced an underwritten public offering of 3,480,000 American depositary shares at $5 apiece to raise $17.4 million in gross proceeds.

The company also granted underwriters a 30-day option to buy up to an additional 522,000 of the ADSs offered.

Akari plans to use funds raised for general corporate purposes.

The offering is expected to close by Oct. 20 with Cantor Fitzgerald & Co., William Blair & Co. LLC and Canaccord Genuity Inc. acting as joint book-running managers.